dc.contributor.author | Brown, CL | |
dc.contributor.author | Whitehouse, MW | |
dc.contributor.author | Tiekink, ERT | |
dc.contributor.author | Bushell, GR | |
dc.date.accessioned | 2017-05-03T11:28:13Z | |
dc.date.available | 2017-05-03T11:28:13Z | |
dc.date.issued | 2008 | |
dc.date.modified | 2011-06-13T22:57:56Z | |
dc.identifier.issn | 0925-4692 | |
dc.identifier.doi | 10.1007/s10787-007-0017-6 | |
dc.identifier.uri | http://hdl.handle.net/10072/21294 | |
dc.description.abstract | Metallic gold (Auis a likely biotransformation product of monovalent gold, Au(I) whenever it is dissociated from in vivo ligands, Auࠢeing formed either by bioreduction or by spontaneous dismutation (with co-production of trivalent gold). This review discusses the preparation and some biologically relevant properties of colloidal metallic gold (CMG) in its nano-particulate form. Tyndall's purple, a well characterised preparation of CMG, shows potent anti-arthritic activity in rats, approximately 103 times that of sodium aurothiomalate (Myocrysin). Even more remarkable is its broader spectrum of action in rats compared to this classic DMARD. | |
dc.description.peerreviewed | Yes | |
dc.description.publicationstatus | Yes | |
dc.language | English | |
dc.language.iso | eng | |
dc.publisher | Birkhauser Verlag | |
dc.publisher.place | Switzerland | |
dc.relation.ispartofstudentpublication | N | |
dc.relation.ispartofpagefrom | 133 | |
dc.relation.ispartofpageto | 137 | |
dc.relation.ispartofjournal | Inflammopharmacology | |
dc.relation.ispartofvolume | 16 | |
dc.rights.retention | Y | |
dc.subject.fieldofresearch | Pharmacology and pharmaceutical sciences | |
dc.subject.fieldofresearchcode | 3214 | |
dc.title | Colloidal metallic gold is not bio-inert | |
dc.type | Journal article | |
dc.type.description | C1 - Articles | |
dc.type.code | C - Journal Articles | |
gro.date.issued | 2008 | |
gro.hasfulltext | No Full Text | |
gro.griffith.author | Bushell, Gillian R. | |